Benefits of combining SGLT2 inhibitors and pioglitazone on risk of MASH in type 2 diabetes—A real‐world study.
- Published in:
- Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 574, doi. 10.1111/dom.16049
- By:
- Publication type:
- Article
Works by Mak, Jimmy Ho‐Cheung
Results: 2
1
2
Serum thrombospondin‐2 level changes with liver stiffness improvement in patients with type 2 diabetes.
- Published in:
- Clinical Endocrinology, 2024, v. 100, n. 3, p. 230, doi. 10.1111/cen.15010
- By:
- Publication type:
- Article